Herbal Formula Science (대한한의학방제학회지)

The Korean Medicine Society for the Herbal Formula Study (대한한의학방제학회)
권호 표지
DOI QR코드

DOI QR Code

The Effect of overcoming the TRAIL resistance through bufalin in EJ human bladder cancer cell

EJ 인간 방광암 세포에서 bufalin 의 TRAIL 저항성 극복 효과

  • Hong, Su Hyun (Department of Biochemistry, College of Korean Medicine, Dong-Eui University)
  • 홍수현 (동의대학교 한의과대학 생화학교실)
  • Received : 2017.05.10
  • Accepted : 2017.05.24
  • Published : 2017.05.31
Download PDF
⟨ Previous Next ⟩

Abstract

Objectives : Bufalin is one of the bioactive component of 'Sum Su (蟾酥)', which is obtained from the skin and parotid venom gland of toad. Bufalin has been known to possess the inhibitory effects on cell proliferation and inducing apoptosis in various cancer cells. The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) has concerned, because it can selectively induce apoptotic cell death in many types of malignant cells, while it is relatively non-toxic to normal cells. Here, we investigated whether bufalin can trigger TRAIL-induced apoptotic cell death in EJ human bladder cancer cells. Methods : Effects on the cell viability and apoptotic activity were quantified using MTT assay and flow cytometry analysis, respectively. To investigate the morphological change of nucleus, DAPI staining was performed. Protein expressions were measured by immunoblotting. Results : A combined treatment with bufalin (10 nM) and TRAIL (50 ng/ml) significantly promoted TRAIL-mediated growth inhibition and apoptosis in EJ cells. The apoptotic effects were associated with the up-regulation of death receptor proteins, and the down-regulation of cFLIP and XIAP. Moreover, our data showed that bufalin and TRAIL combination activated caspases and subsequently increased degradation of poly(ADP-ribose) polymerase. Conclusions : Taken altogether, the nontoxic doses of bufalin sensitized TRAIL-mediated apoptosis in EJ cells. Therefore, bufalin might be an effective therapeutic strategy for the safe treatment of TRAIL-resistant bladder cancers.

Keywords

References

  1. Guancial EA, Roussel B, Bergsma DP, Bylund KC, Sahasrabudhe D, Messing E, Mohile SG, Fung C. Bladder cancer in the elderly patient: challenges and solutions. Clin Interv Aging. 2015 ; 10 : 939-49.
  2. Shamseddine A, Saleh A, Charafeddine M, Seoud M, Mukherji D, Temraz S, Sibai AM. Cancer trends in Lebanon: a review of incidence rates for the period of 2003-2008 and projections until 2018. Popul Health Metr. 2014 ; 12(1) : 4. https://doi.org/10.1186/1478-7954-12-4
  3. Syn SJ. Systemic Treatment for Metastatic Bladder Cancer. Kor J Med. 2015 ; 29(5) : 515-21.
  4. Lim B, Allen JE, Prabhu VV, Talekar MK, Finnberg NK, El-Deiry WS. Targeting TRAIL in the treatment of cancer: new developments. Expert Opin Ther Targets. 2015 ; 19(9) : 1171-85. https://doi.org/10.1517/14728222.2015.1049838
  5. Ploeg M, Aben KK and Kiemeney LA: The present and future burden of urinary bladder cancer in the world. World J Urol. 2009 ; 27(3) : 289-93. https://doi.org/10.1007/s00345-009-0383-3
  6. Dai X, Zhang J, Arfuso F, Chinnathambi A, Zayed ME, Alharbi SA, Kumar AP, Ahn KS, Sethi G. Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapy. Exp Biol Med (Maywood). 2015 ; 240(6) : 760-73. https://doi.org/10.1177/1535370215579167
  7. Szliszka E, Mazur B, Zydowicz G, Czuba ZP, Krol W. TRAIL-induced apoptosis and expression of death receptor TRAIL-R1 and TRAIL-R2 in bladder cancer cells. Folia Histochem Cytobiol. 2009; 47(4) : 579-85.
  8. Trivedi R, Mishra DP. Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells. Front Oncol. 2015; 5 : 69.
  9. Shuzhen C, Lei F, Shruti MR, Ping Y, Fadlo RK and Sun SY. Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of Geranylgeranyltransferase I inhibition-mediated augmentation of TRAILinduced apoptosis. Mol Cancer. 2010 ; 9 : 23. https://doi.org/10.1186/1476-4598-9-23
  10. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene. 2003 ; 22(53) : 8628-33. https://doi.org/10.1038/sj.onc.1207232
  11. Thorburn A, Behbakht K, Ford H. TRAIL receptortargeted therapeutics: resistance mechanisms and strategies to avoid them. Drug Resist Updat. 2008 ; 11(1-2) : 17-24. https://doi.org/10.1016/j.drup.2008.02.001
  12. Yan S, Qu X, Xu L, Che X, Ma Y, Zhang L, Teng Y, Zou H, Liu Y. Bufalin enhances TRAIL-induced apoptosis by redistributing death receptors in lipid rafts in breast cancer cells. Anticancer Drugs. 2014; 25(6) : 683-9.
  13. White-Gilbertson SJ, Kasman L, McKillop J, Tirodkar T, Lu P, Voelkel-Johnson C. Oxidative stress sensitizes bladder cancer cells to TRAIL mediated apoptosis by down-regulating antiapoptotic proteins. J Urol. 2009 ; 182(3) : 1178-85. https://doi.org/10.1016/j.juro.2009.05.005
  14. LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, Fong S, Schwall R, Sinicropi D, Ashkenazi A. Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med. 2002 ; 8(3) : 274-81. https://doi.org/10.1038/nm0302-274
  15. Ahmed SM, Wu X, Jin X, Zhang X, Togo Y, Suzuki T, Li Y, Kanematsu A, Nojima M, Yamamoto S, Sugimoto M, Kakehi Y. Synergistic induction of apoptosis by mapatumumab and anthracyclines in human bladder cancer cells. Oncol Rep. 2015 ; 33(2) : 566-72. https://doi.org/10.3892/or.2014.3654
  16. Yin PH, Liu X, Qiu YY, Cai JF, Qin JM, Zhu HR, Li Q. Anti-tumor activity and apoptosisregulation mechanisms of bufalin in various cancers: new hope for cancer patients. Asian Pac J Cancer Prev. 2012 ; 13(11) : 5339-43. https://doi.org/10.7314/APJCP.2012.13.11.5339
  17. Qi F, Li A, Inagaki Y, Kokudo N, Tamura S, Nakata M, Tang W. Antitumor activity of extracts and compounds from the skin of the toad Bufo bufo gargarizans Cantor. Int Immunopharmacol 2011 ; 11(3) : 342-9. https://doi.org/10.1016/j.intimp.2010.12.007
  18. http://www.koreantk.com/
  19. Park C, Hong SH, Choi SH, Lee SR, Lean SH, Choi YH. Sagantang-induced Apoptotic Cell Death is Associated with the Activation of Caspases in AGS Human Gastric Carcinoma Cells. J Life Sicence. 2015 ; 25(12) : 1384-1392.
  20. Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L, Pai R, Hymowitz SG, Ashkenazi A. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor- related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem. 2005 ; 280(3) : 2205-12. https://doi.org/10.1074/jbc.M410660200
  21. Shalini S, Dorstyn L, Dawar S, Kumar S. Old, new and emerging functions of caspases. Cell Death Differ. 2015 ; 22(4) : 526-39. https://doi.org/10.1038/cdd.2014.216
  22. Duriez PJ, Shah GM. Cleavage of poly(ADP-ribose) polymerase: a sensitive parameter to study cell death. Biochem Cell Biol. 1997 ; 75(4) : 337-49. https://doi.org/10.1139/o97-043
  23. Yin XM. Signal transduction mediated by Bid, a pro-death Bcl-2 family proteins, connects the death receptor and mitochondria apoptosis pathways. Cell Res. 2010 ; 10(3) : 161-7. https://doi.org/10.1038/sj.cr.7290045
  24. Kim JH, Kim MJ, Choi KC, Son J. Quercetin sensitizes pancreatic cancer cells to TRAILinduced apoptosis through JNK-mediated cFLIP turnover. Int J Biochem Cell Biol. 2016 ; 78 : 327-34. https://doi.org/10.1016/j.biocel.2016.07.033
  25. Safa AR. c-FLIP, a master anti-apoptotic regulator. Exp Oncol. 2012 ; 34(3) : 176-84.
  26. Ewald F, Ueffing N, Brockmann L, Hader C, Telieps T, Schuster M, Schulz WA, Schmitz I. The role of c-FLIP splice variants in urothelial tumours. Cell Death Dis. 2011; 2 : e245. https://doi.org/10.1038/cddis.2011.131
  27. Jin CY, Park C, Hwang HJ, Kim GY, Choi BT, Kim BW, Choi YH. Naringenin up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer A549 cells. Mol Nutr Food Res. 2011 ; 55(2) : 300-9. https://doi.org/10.1002/mnfr.201000024
  28. Li Y, Jin X, Li J, Jin X, Yu J, Sun X, Chu Y, Xu C, Li X, Wang X, Kakehi Y, Wu X. Expression of TRAIL, DR4, and DR5 in bladder cancer: correlation with response to adjuvant therapy and implications of prognosis. Urology. 2012 ; 79(4) : 968.e7-15. https://doi.org/10.1016/j.urology.2011.11.011
  29. Chen Z, Sangwan V, Banerjee S, Chugh R, Dudeja V, Vickers SM, Saluja AK. Triptolide sensitizes pancreatic cancer cells to TRAILinduced activation of the death receptor pathway. Cancer Lett. 2014 ; 348(1-2) : 156-66. https://doi.org/10.1016/j.canlet.2014.03.016